Rachel Francis, PA
Physician Assistant · Gainesville, FLNPI 1699045526
Payments from drug & device makers
Across 136 payments — averaging $19.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Boehringer Ingelheim$164
- Dexcom, Inc.$149
- AstraZeneca$119
- Abbott$89
- Tandem Diabetes Care, Inc.$61
- plus $636 from 18 others
What the payments were for
- Food & beverage$2,628100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 82 | $1,410 |
| Boehringer Ingelheim | 9 | $164 |
| Dexcom, Inc. | 3 | $149 |
| AstraZeneca | 1 | $119 |
| Abbott | 5 | $89 |
| Tandem Diabetes Care, Inc. | 4 | $61 |
| Lilly USA, LLC | 4 | $60 |
| Ascensia Diabetes Care US Inc. | 1 | $60 |
| Bayer | 3 | $60 |
| Sanofi | 1 | $53 |
| Medtronic | 3 | $48 |
| Insulet Corporation | 3 | $45 |
| Corcept Therapeutics | 2 | $45 |
| AbbVie | 3 | $43 |
| Xeris Pharmaceuticals, Inc. | 2 | $40 |
| Sequel Med Tech, LLC | 1 | $34 |
| Amgen | 2 | $27 |
| Ascendis Pharma Endocrinology Inc | 1 | $23 |
| Sanofi-aventis U.S. LLC | 1 | $19 |
| Halozyme Inc | 1 | $18 |
| Amryt Pharma Holdings Ltd | 1 | $17 |
| GSK | 1 | $17 |
| Novartis | 1 | $14 |
| Kyowa Kirin, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DEXCOM G7 GSS (161)$120
- FARXIGA$119
- Ozempic$102
How this compares
$2,628 in reported general payments places this provider in the 80th percentile of 8,062 physician assistant providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 243 | $349,921 |
| MounjaroTirzepatide | 158 | $200,518 |
| TrulicityDulaglutide | 86 | $113,952 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 66 | $102,097 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 68 | $89,779 |
| JardianceEmpagliflozin | 74 | $80,899 |
| Tresiba Flextouch U-100Insulin Degludec | 95 | $60,390 |
| FarxigaDapagliflozin Propanediol | 45 | $54,852 |
| Tresiba Flextouch U-200Insulin Degludec | 29 | $48,067 |
| RybelsusSemaglutide | 29 | $46,864 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 29 | $44,506 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 35 | $41,397 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 31 | $24,952 |
| NovologInsulin Aspart | 46 | $16,973 |
| Gvoke Hypopen 2-PackGlucagon | 21 | $15,397 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $1,410 | $413,757318 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $60 | $325,028276 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $19 | $102,09766 claims |
| Boehringer IngelheimJardiance | $164 | $80,89974 claims |
| AstraZenecaFarxiga | $119 | $54,85245 claims |
| AbbVieSynthroid | $43 | $4,49743 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,062 physician assistant providers in Florida.
Other physician assistant in Gainesville
- Ashley MillerGainesville$328K
- Mary Kate VellisGainesville$79K
- Kelsey KimballGainesville$41K
- Richard MarshallPort Orange$988K
- Audrey BeckerSt Augustine$689K
- Kevin WilliamsTampa$647K
- Brian BonomoLecanto$559K
- Melissa SingletonOcala$482K
- Reeli ReinuMaitland$427K
- Jeanelle KingMiami$424K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.